Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosurgery in Europe

This article was originally published in Start Up

Executive Summary

It appears that the climate is becoming more favorable for surgical sealants and adhesives in Europe, according to "European Markets for New and Emerging Wound Closure Products and Techniques" a report published in April 2007 by Medtech Insight, because health care payers want to bridge the gap between an aging population's high-technological medical product requirements and regional health care cost containment initiatives.

You may also be interested in...



An Open Market for Vascular Closure Devices

Sensing a largely untapped opportunity in vascular closure, due to the drawbacks of manual compression and issues with first-generation products, device companies are working on newer-generation devices that both avoid the problems associated with the older devices and address the disadvantages of manual compression.

An Open Market for Vascular Access Closure Devices

After an initial warm welcome for first-generation femoral artery closure devices--including a few high-profile exits--sales have stalled. Early devices are flawed, indicating the technical challenge is tougher than it looks. A dozen or so start-ups are trying to address the technology problems that have hampered the pioneers. The newcomers face high hurdles as early experience with first generation devices temper clinician and investor enthusiasm. All will have to prove, in large, rigorous clinical trials, that devices are more complication-free and are as easy-to-use as market leader Angio-Seal, and that they're at least as safe, if not safer, than manual compression. But although start-ups face a great of skepticism about particular technologies, they also inherit a $350 million market made up of devices with an average selling price of $200, which is an endorsement of this new device market. At the same time, an enormous opportunity remains in the 75% of the market that remains unpenetrated.

Surgical Sealants: Is there a Cohesive Strategy?

Surgical sealants have promise, but can a host of companies convince surgeons that these adjunctive therapies are "need to have" not "nice to have" technologies?

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT037501

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel